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Abstract
Computed tomography screening for early diagnosis of lung cancer is one of the more potentially
useful strategies, aside from smoking cessation programmes, for reducing mortality and improving the
current poor survival from this disease. The long-term success of lung cancer screening will be
dependent upon identifying populations at sufficient risk in order to maximise the benefit-to-harm
ratio of the intervention. Risk prediction models could potentially play a major role in the selection of
high-risk individuals who would benefit most from screening intervention programmes for the early
detection of lung cancer. Improvements of developed lung cancer risk prediction models (through
incorporation of objective clinical factors and genetic and molecular biomarkers for precise and
accurate estimation of risks), demonstration of their clinical usefulness in decision making, and their
use in future screening programmes are the focus of current research.
Introduction and context
Lung cancer is the most commonly diagnosed cancer
worldwideandtheleadingcauseofallcancerdeaths[1,2].
The disease is diagnosed mostly at an advanced stage,
when surgical resection is unlikely to be a treatment
option, thus leading to poor survival rates [3]. The 5-year
survivalrateforallstagesoflungcancerrangesfrom6%in
the UK [4] to 15% in the US, in contrast to a survival rate
of about 70% for stage I lung cancer, suggesting that early
diagnosis and treatment of the disease would vastly
improve outcome and reduce mortality [5].
Computed tomography (CT) screening has been high-
lightedasoneofthepotentialstrategiesforearlydiagnosis
of lung cancer [6-9]. However, the lung cancer research
community is eagerly awaiting results of various ongoing
screening trials (Table 1) evaluating the potential benefit
of CT screening [6]. For optimum cost-effectiveness, a
population of individuals at sufficiently high risk of the
disease needs to be identified so that the benefit-to-harm
ratio of the screeningcan bemaximized [10].The needfor
the selection of a high-risk population for lung cancer
screeninghasrenewedinternationalinterestindeveloping
methods for the prediction of an individual’sr i s ko f
developing lung cancer.
There are now a number of lung cancer risk prediction
models, including those of Peto and colleagues [11], Bach
and colleagues [12], Spitz and colleagues [13], and the
Liverpool Lung Project (LLP) [14]. These models use a
selection of data which includes the patient’ss e l f - r e p o r t e d
information on epidemiological and clinical risk factors
with local lung cancer incidence data to predict the
individual’s risk within a specified period. For example,
the LLP risk model included information on the patient’s
smoking duration, prior diagnosis of pneumonia, asbes-
tos exposure, previous diagnosis of a non-melanoma
malignant tumour, and family history of lung cancer
(using age of diagnosis in first-degree relatives). The
individual’s 5-year absolute risk of lung cancer was then
estimated by combining the relative risk model with age-
and gender-specific lung cancer incidence rates [14].
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design, recruitment, and analysis of studies of lung
cancer prevention programmes, potentially reducing the
sample size required to achieve the desired statistical
power for outcome benefit [12]. We recently discussed
the potential use of the LLP risk model in the design of a
CT screening trial and a population screening interven-
tion programme in the event of positive results from the
trial [15]. The results reveal that increasing the minimum
5-year absolute risk criterion of individuals to be selected
in a screening trial from 1.5% to 2.5% reduces the
required sample size by approximately one-third.
Recent advances
Ideally, the lung cancer community needs to be develop-
ing risk prediction models that embrace not only
epidemiological parameters but also emerging genetic
and molecular biomarkers [16] (Figure 1). Recently, three
major genome-wide association studies in lung cancer
identified genetic susceptibility genes strongly associated
with lung cancer [17-19]. The promise of the expansion of
genomic research is that many more biomarkers will be
identified and validated in case control studies with
specimens such as serum, plasma, bronchial lavage,
induced sputum, or tissue. It is anticipated that the
addition of these biomarkers or their combinations into
existing risk models would improve the precision and
accuracy of the predicted risks [16,20]. This has led to the
recent quest toidentifythebestmethodologyforassessing
improvements in risk models, which incorporate addi-
tional risk factors such as genetic biomarkers. The recent
emergence of new methodologies such as decision curve
analysis and relative utility of risk models has put
assessment of risk model performance in clinical perspec-
tive rather than using pure statistical measure [21-24].
Recently, two specific respiratory risk factors have been
highlighted in the development of lung cancer, that of
pre-existing tuberculosis [25] and chronic obstructive
pulmonary disease (COPD) [26]. The inclusion of these
risk factors, particularly an objective COPD measure-
ment (ratio of forced expiratory volume in 1 second to
forced expiratory capacity, or FEV1/FEC) and other
validated clinical information, in place of self-reported
responses to questionnaire data would alleviate the
impact of recall bias on the estimated risks.
Implications for clinical practice
In recognizing the impact of late diagnosis of cancer, the
Cancer Reform Strategy recently established a National
Awareness and Early Diagnosis Initiative (NAEDI) with a
view to continuously promote early diagnosis in the large
majorityofpatientswho presentwithsymptoms[27].The
NAEDI-hypothesized pathways for late presentation
include low awareness of the signs and symptoms of
cancer among the public as well as delay occurring within
primary care, which may be due to inadequate access to a
decision tool that may assist general practices (GPs) to
reassureorobservepatients,request furtherinvestigations,
or refer patients to specialist services. As a result, there are
now plans to equip every GP within a period of 5 years
with a computerized algorithm to predict cancer risk [28].
Table 1. Low-dose computed tomography randomized clinical trials for lung cancer screening
Country, study name Patients
receiving
LDCT
Patients in
control arm
Study design Selection of participants Report date Publications
The Netherlands and
Belgium, NELSON
8000
a 8000
a LDCT versus no
intervention
Smokers and ex-smokers
with a history of >30 PKS
Recruitment completed
Report 2015
[9,33]
Denmark, NELSON 2000
a 2000
a LDCT versus no
intervention
Smokers and ex-smokers
with a history of >30 PKS
Recruitment completed
Report 2015
[34]
Italy, Italung-CT 1500 1500 LDCT versus no
intervention
Smokers and ex-smokers
with a history of >30 PKS
Report 2005 [35]
DANTE 1276 1196 Chest X-ray and sputum
cytology for all patients in
year 1. LDCT versus
yearly review.
Smokers with a history
of >20 PKS
Report 2007 [36]
France, (pilot)
Dépiscan
330 291 LDCT versus chest X-ray Smokers (64%) and
ex-smokers (36%)
Report 2006 [37]
USA, LSS feasibility
study
1600 1658 LDCT versus chest X-ray Smokers with a history
of ≥30 PKS
Report 2005 [38]
USA, NLST 26,500 26,500 LDCT versus chest X-ray Smokers and ex-smokers
with a history of ≥30 PKS
Recruitment completed [39,40]
aPlanned recruitment. Pack years (PKS) = (packs smoked per day) × (years as a smoker). DANTE, Randomized Study on Lung Cancer Screening With
Low-Dose Spiral Computed Tomography; Dépiscan, Pilot Study to Evaluate Low Dose Spiral CT Scanning as a Screening Method for Bronchial Carcinoma;
Italung-CT, Multicentric Randomised Clinical Trial for Lung Cancer Screening with Low-Dose CT; LDCT, low-dose computed tomography; LSS, Lung
Screening Study; NELSON, Dutch-Belgian Randomised Lung Cancer Screening Trial; NLST, National Lung Screening Trial. Table modified and updated from
Field & Duffy, Br J Cancer 2008 [6]. Copyright © 2008 Cancer Research UK.
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populations and demonstrated to be clinically useful for
making decisions regarding patient treatment or clinical
interventions before they can be acceptable as decision
tools by clinicians [29,30]. This is rarely undertaken as
only a few existing models, including those for lung
cancer, have been validated in independent populations.
The validation of the LLP risk model in data from three
independent studies revealed promising results (unpub-
lished data); the model displayed good clinical utility by
performing better than all other alternative approaches
for making decisions about whom to screen or not to
screen for lung cancer.
The LLP risk model has been implemented in a feasibility
study (funded by the Knowsley Primary Care Trust, UK)
in the primary care setting [31] and is being evaluated in
other high-risk GP locations. The outcome of this study
will provide important public health guidance as to how
to identify individuals who are at risk of developing lung
cancer prior to developing symptoms. Also, an assess-
ment of the model in the UK Lung Cancer CT Screening
Study (UKLS) trial [32] was successful; therefore, it has
been recommended as a major tool in stratification of
patients to be screened in the general population.
In conclusion, screening and other clinical interventions
for prevention and early diagnosis of lung cancer would
be cost-effective if targeted on patients at sufficient high
risk. Risk models provide useful tools to stratify patients
into high or low risk and provide counselling regarding
level of risks, motivating changes in personal lifestyle.
Figure 1. Lung cancer risk model decision cascade
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Mirror images of shared aspects of the cascades of lung cancer risk assessment (left) and early detection (right) are shown. These cascades move from clinical
and epidemiological assessments to molecular epidemiological assessments to biomarker assessments in non-lung samples and finally to biomarker
assessments in lung samples. They merge in the middle with the identification of the highest-risk individuals who need computed tomography (CT) screening.
Individuals with a positive CT scan will be entered into clinical workup and treatment protocols. Those with a negative CT scan are clearly at a high risk and
should be considered for prevention research studies. SNP, single-nucleotide polymorphism. Image originally published in Field, Cancer Prev Res 2008 [16].
Copyright © 2008 American Association of Cancer Research.
Page 3 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:38 http://f1000.com/reports/medicine/content/2/38Abbreviations
COPD, chronic obstructive pulmonary disease; CT,
computed tomography; GP, general practice; LLP, Liver-
pool Lung Project; NAEDI, National Awareness and Early
Diagnosis Initiative.
Competing interest
The authors declare that they have no competing interests.
Acknowledgments
OYR is supported by the Roy Castle Lung Cancer
Foundation (UK).
References
1. Hirsch FR, Lippman SM: Advances in the biology of lung cancer
chemoprevention. J Clin Oncol 2005, 23:3186-97.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.
CA Cancer J Clin 2005, 55:74-108.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J,
Zhu J, Johnson DH; Eastern Cooperative Oncology Group: Com-
parison of four chemotherapy regimens for advanced non-
small-cell lung cancer. N Engl J Med 2002, 346:92-8.
4. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N,
Quinn MJ, Brenner H, Estève J: Trends and socioeconomic
inequalities in cancer survival in England and Wales up to
2001. Br J Cancer 2004, 90:1367-73.
5. Ganti AK, Mulshine JL: Lung cancer screening: panacea or pipe
dream? Ann Oncol 2005, 16(Suppl 2):ii215-9.
6. Field JK, Duffy SW: Lung cancer screening: the way forward. Br J
Cancer 2008, 99:557-62.
7. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP,
McGuinness G, Miettinen OS, Libby DM, Pasmantier MW,
Koizumi J, Altorki NK, Smith JP: Early Lung Cancer Action
Project: overall design and findings from baseline screening.
Lancet 1999, 354:99-105.
8. Mulshine JL, Sullivan DC: Clinical practice. Lung cancer screen-
ing. N Engl J Med 2005, 352:2714-20.
9. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K,
Vernhout R, van Iersel CA, van den Bergh KA, van ‘t Westeinde S, van
der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de
Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C,
Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A,
Mali W, de Koning HJ: Management of lung nodules detected by
volume CT scanning. N Engl J Med 2009, 361:2221-9.
10. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR: Lung cancer
screening by spiral CT. What is the optimal target popula-
tion for screening trials? Lung Cancer 2002, 38:243-52.
11. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R: Smoking,
smoking cessation, and lung cancer in the UK since 1950:
combination of national statistics with two case-control
studies. BMJ 2000, 321:323-9.
12. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ,
Hsieh LJ, Begg CB: Variations in lung cancer risk among
smokers. J Natl Cancer Inst 2003, 95:470-8.
13. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S,
Etzel CJ: A risk model for prediction of lung cancer. J Natl
Cancer Inst 2007, 99:715-26.
14. Cassidy A, Duffy SW, Myles JP, Liloglou T, Field JK: Lung cancer risk
prediction: a tool for early detection. Int J Cancer 2007, 120:1-6.
15. Duffy SW, Raji OY, Agbaje OF, Allgood PC, Cassidy A, Field JK: Use
of lung cancer risk models in planning research and service
programs in CT screening for lung cancer. Expert Rev Anticancer
Ther 2009, 9:1467-72.
16. Field JK: Lung cancer risk models come of age. Cancer Prev Res
2008, 1:226-8.
17. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D,
Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P,
Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C,
Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A,
McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB,
Hveem K, Vatten L, Linseisen J, et al.: A susceptibility locus for
lung cancer maps to nicotinic acetylcholine receptor subunit
genes on 15q25. Nature 2008, 452:633-7.
18. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q,
Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y,
Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR,
Houlston RS: Genome-wide association scan of tag SNPs
identifies a susceptibility locus for lung cancer at 15q25.1. Nat
Genet 2008, 40:616-22.
F1000 Factor 3.0 Recommended
Evaluated by Terri Beaty 07 Apr 2008
19. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP,
Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN,
Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T,
Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ,
Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ,
Gudbjartsson T, Jones GT, Mueller T, Gottsäter A, Flex A,
Aben KK, de Vegt F, et al.: A variant associated with nicotine
dependence, lung cancer and peripheral arterial disease.
Nature 2008, 452:638-42.
20. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, Hong WK: An
expanded risk prediction model for lung cancer. Cancer Prev
Res 2008, 1:250-4.
21. Baker SG: Putting risk prediction in perspective: relative utility
curves. J Natl Cancer Inst 2009, 101:1538-42.
22. Vickers AJ, Cronin AM, Elkin EB, Gonen M: Extensions to decision
curve analysis, a novel method for evaluating diagnostic tests,
prediction models and molecular markers. BMC Med Inform
Decis Mak 2008, 8:53.
23. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS:
Evaluating the added predictive ability of a new marker:
from area under the ROC curve to reclassification and
beyond. Stat Med 2008, 27:157-72; discussion 207-12.
24. Pepe MS, Janes HE: Gauging the performance of SNPs,
biomarkers, and clinical factors for predicting risk of breast
cancer. J Natl Cancer Inst 2008, 100:978-9.
25. Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, Zhou BS: Facts and
fiction of the relationship between preexisting tuberculosis
and lung cancer risk: a systematic review. Int J Cancer 2009,
125:2936-44.
26. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM: Lung
cancer and chronic obstructive pulmonary disease: needs and
opportunities for integrated research. J Natl Cancer Inst 2009,
101:554-9.
27. Richards MA: The National Awareness and Early Diagnosis
Initiative in England: assembling the evidence. Br J Cancer 2009,
101(Suppl 2):S1-4.
28. The Lancet: General practitioner or computerised algorithm?
Lancet 2010, 375:94.
29. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-
Barbash R, Pfeiffer RM: Cancer risk prediction models: a
workshop on development, evaluation, and application. J
Natl Cancer Inst 2005, 97:715-23.
30. Reilly BM, Evans AT: Translating clinical research into clinical
practice: impact of using prediction rules to make decisions.
Ann Intern Med 2006, 144:201-9.
F1000 Factor 6.0 Must Read
Evaluated by Ewout Steyerberg 13 Sep 2006
31. Ashton M, Mimnagh C, Forrest D, Field J: A pilot study to explore
lung cancer early detection and clinical intervention in a
Page 4 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:38 http://f1000.com/reports/medicine/content/2/38primary care setting in Knowsley, Merseyside. J Thorac Oncol
2008, 3(Suppl 7):S179-257 Abstract PP24.
32. NIHR Health Technology Assessment Programme – Details
of completed HTA project: UK Lung Cancer Screening Trial
(UKLS) - Feasibility study and protocol development. [http://
www.hta.ac.uk/1752]
33. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET,
Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ:
Risk-based selection from the general population in a
screening trial: selection criteria, recruitment and power
for the Dutch-Belgian randomised lung cancer multi-slice CT
screening trial (NELSON). Int J Cancer 2007, 120:868-74.
34. Pedersen JH, Dirksen A, Olsen JH: [Screening for lung cancer
with low-dosage CT]. Ugeskr Laeger 2002, 164:167-70.
35. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De
Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of
lung cancer with low dose spiral CT: results of a three year
pilot study and design of the randomised controlled trial
‘‘Italung-CT’’. Radiol Med (Torino) 2005, 109:17-26.
36. Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E,
Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Alloisio M,
Incarbone M, Testori A, Destro A, Cappuzzo F, Roncalli M,
Santoro A, Ravasi G; DANTE Study Group: Lung cancer screening
with spiral CT Baseline results of the randomized DANTE
trial. Lung Cancer 2008, 59:355-63.
37. Blanchon T, Bréchot JM, Grenier PA, Ferretti GR, Lemarié E,
Milleron B, Chagué D, Laurent F, Martinet Y, Beigelman-Aubry C,
Blanchon F, Revel MP, Friard S, Rémy-Jardin M, Vasile M, Santelmo N,
Lecalier A, Lefébure P, Moro-Sibilot D, Breton JL, Carette MF,
Brambilla C, Fournel F, Kieffer A, Frija G, Flahault A; Dépiscan Group:
Baseline results of the Depiscan study: a French randomized
pilot trial of lung cancer screening comparing low dose CT
scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007, 58:50-8.
38. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS,
Prorok PC, Ascher S, Bailey W, Brewer B, Church T, Engelhard D,
Ford M, Fouad M, Freedman M, Gelmann E, Gierada D, Hocking W,
Inampudi S, Irons B, Johnson CC, Jones A, Kucera G, Kvale P,
Lappe K, Manor W, Moore A, Nath H, Neff S, Oken M, Plunkett M,
et al.; Lung Screening Study Research Group: Final results of the
Lung Screening Study, a randomized feasibility study of spiral
CT versus chest X-ray screening for lung cancer. Lung Cancer
2005, 47:9-15.
39. Ford LG, Minasian LM, McCaskill-Stevens W, Pisano ED, Sullivan D,
Smith RA: Prevention and early detection clinical trials:
opportunities for primary care providers and their patients.
CA Cancer J Clin 2003, 53:82-101.
40. National Cancer Institute – U.S. National Institutes of
Health: National Lung Screening Trial (NLST). [http://www.
cancer.gov/nlst]
Page 5 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:38 http://f1000.com/reports/medicine/content/2/38